| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study O Hansson, H Zetterberg, P Buchhave, E Londos, K Blennow, L Minthon The Lancet Neurology 5 (3), 228-234, 2006 | 2169 | 2006 |
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ... Jama 302 (4), 385-393, 2009 | 1467 | 2009 |
| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 994 | 2020 |
| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 977 | 2020 |
| Brain charts for the human lifespan RAI Bethlehem, J Seidlitz, SR White, JW Vogel, KM Anderson, ... Nature 604 (7906), 525-533, 2022 | 975 | 2022 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 965 | 2020 |
| Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio, JD Sparks, AM Wessels, ... Jama 330 (6), 512-527, 2023 | 921 | 2023 |
| Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease S Budd Haeberlein, PS Aisen, F Barkhof, S Chalkias, T Chen, S Cohen, ... The journal of prevention of Alzheimer's disease 9 (2), 197-210, 2022 | 876 | 2022 |
| Cerebrospinal fluid levels ofβ-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia P Buchhave, L Minthon, H Zetterberg, ÅK Wallin, K Blennow, O Hansson Archives of general psychiatry 69 (1), 98-106, 2012 | 808 | 2012 |
| Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity S Palmqvist, M Schöll, O Strandberg, N Mattsson, E Stomrud, H Zetterberg, ... Nature communications 8 (1), 1214, 2017 | 774 | 2017 |
| Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease MM Zeron, O Hansson, N Chen, CL Wellington, BR Leavitt, P Brundin, ... Neuron 33 (6), 849-860, 2002 | 747 | 2002 |
| Biomarkers for neurodegenerative diseases O Hansson Nature medicine 27 (6), 954-963, 2021 | 723 | 2021 |
| Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers GB Frisoni, M Boccardi, F Barkhof, K Blennow, S Cappa, K Chiotis, ... The Lancet Neurology 16 (8), 661-676, 2017 | 676 | 2017 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 645 | 2019 |
| CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimer's & dementia 14 (11), 1470-1481, 2018 | 631 | 2018 |
| Blood-based biomarkers for Alzheimer's disease: towards clinical implementation CE Teunissen, IMW Verberk, EH Thijssen, L Vermunt, O Hansson, ... The Lancet Neurology 21 (1), 66-77, 2022 | 628 | 2022 |
| Plasma β-amyloid in Alzheimer’s disease and vascular disease S Janelidze, E Stomrud, S Palmqvist, H Zetterberg, D Van Westen, ... Scientific reports 6 (1), 26801, 2016 | 627 | 2016 |
| Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity D Lindqvist, S Janelidze, P Hagell, S Erhardt, M Samuelsson, L Minthon, ... Biological psychiatry 66 (3), 287-292, 2009 | 592 | 2009 |
| Amyloid biomarkers in Alzheimer's disease K Blennow, N Mattsson, M Schöll, O Hansson, H Zetterberg Trends in pharmacological sciences 36 (5), 297-309, 2015 | 557 | 2015 |
| CSF and blood biomarkers for Parkinson's disease L Parnetti, L Gaetani, P Eusebi, S Paciotti, O Hansson, O El-Agnaf, ... The Lancet Neurology 18 (6), 573-586, 2019 | 555 | 2019 |
Henrik ZetterbergSahlgrenskaE-mail confirmado em clinchem.gu.se
